Related Experiment Video
Updated: Oct 2, 2026
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
Published on: June 17, 2016
Inhibition of rat liver fibrogenesis through noradrenergic antagonism
Liliane Dubuisson1, Alexis Desmoulière, Boris Decourt
1Groupe de Recherches pour l'Etude du Foie, INSERM E9917, Université Victor Segalen Bordeaux 2, Bordeaux, France.
Abstract:
The effect of adrenergic innervation and/or circulating catecholamines on the function of liver fibrogenic cells is poorly understood. Our aim was to investigate the effects of noradrenergic antagonism on carbon tetrachloride (CCl4)-induced liver fibrosis in rats. Two weeks of CCl4 induced an approximately 5-fold increase in the area of fibrosis as compared with controls. The addition of 6-hydroxydopamine (OHDA), a toxin that destroys noradrenergic fibers, decreased fibrosis by 60%. After 6 weeks of CCl4, the area of fibrosis increased about 30-fold in CCl4-treated animals and was decreased by 36% with OHDA. At 2 weeks, OHDA abrogated the CCl4-induced increase in mRNA level of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), an inhibitor of extracellular matrix degradation, and it greatly reduced it at 6 weeks. Finally, when rats treated with CCl4 for 2 weeks also received prazosin, an antagonist of alpha1-adrenergic receptors, fibrosis was decreased by 83%. In conclusion, destruction of noradrenergic fibers or antagonism of noradrenergic signaling through alpha1 receptors inhibited the development of liver fibrosis. Because adrenoreceptor antagonists have a very sound safety profile, they appear as attractive drugs to reduce liver fibrogenesis.
Insights
Noradrenergic signaling promotes liver fibrosis. Blocking these pathways with 6-hydroxydopamine (OHDA) or prazosin significantly reduced fibrosis in a rat model, suggesting potential therapeutic strategies.
Area of Science:
- Hepatology
- Fibrosis research
- Adrenergic signaling
Background:
- The role of adrenergic innervation and catecholamines in liver fibrogenesis is not well understood.
- Liver fibrosis, a precursor to cirrhosis, involves excessive extracellular matrix deposition.
- Understanding regulatory pathways is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the impact of noradrenergic antagonism on carbon tetrachloride (CCl4)-induced liver fibrosis in rats.
- To evaluate the efficacy of 6-hydroxydopamine (OHDA) and prazosin in mitigating liver fibrosis.
- To explore the modulation of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) by noradrenergic signaling.
Main Methods:
- Induction of liver fibrosis in rats using carbon tetrachloride (CCl4).
- Administration of 6-hydroxydopamine (OHDA) to destroy noradrenergic fibers.
- Treatment with prazosin, an alpha1-adrenergic receptor antagonist.
- Assessment of fibrosis area and mRNA levels of TIMP-1.
Main Results:
- CCl4 administration led to a significant increase in liver fibrosis area.
- OHDA treatment reduced fibrosis by 60% at 2 weeks and 36% at 6 weeks.
- Prazosin decreased fibrosis by 83% after 2 weeks of CCl4 treatment.
- OHDA abrogated or greatly reduced CCl4-induced increases in TIMP-1 mRNA levels.
Conclusions:
- Noradrenergic fibers and alpha1-adrenergic receptor signaling play a significant role in promoting liver fibrosis.
- Inhibiting noradrenergic pathways effectively reduces liver fibrogenesis in a rat model.
- Adrenoreceptor antagonists represent promising therapeutic agents for managing liver fibrosis due to their safety profile.
